Safety profile of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: long-term interim results from the ENDORSE extension study

被引：0

作者：

Pozzilli, C. ^{[1
]}

Phillips, J. T. ^{[2
]}

Fox, R. J. ^{[3
]}

Selmaj, K. ^{[4
]}

Zhang, R. ^{[5
]}

Novas, M. ^{[5
]}

Sweetser, M. T. ^{[5
]}

Viglietta, V. ^{[5
]}

Gold, R. ^{[6
]}

机构：

[1] Univ Roma La Sapienza, Dept Neurol & Psychiat, Fac Med, I-00185 Rome, Italy

[2] Baylor Inst Immunol Res, Multiple Sclerosis Program, Dallas, TX USA

[3] Cleveland Clin, Mellen Ctr Multiple Sclerosis Treatment & Res, Cleveland, OH 44106 USA

[4] Med Univ Lodz, Dept Neurol, Lodz, Poland

[5] Biogen Idec Inc, Cambridge, MA USA

[6] Ruhr Univ Bochum, St Josef Hosp, Dept Neurol, Bochum, Germany

来源：

JOURNAL OF NEUROLOGY | 2014年 / 261卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

PP4153

引用

页码：S439 / S439

页数：1

共 50 条

[41] 4-year follow-up of delayed-release dimethyl fumarate treatment in relapsing-remitting multiple sclerosis (RRMS): integrated clinical efficacy data from DEFINE, CONFIRM, and the ENDORSE extension study
Gold, R.
Phillips, J. T.
Bar-Or, A.
Kappos, L.
Zhang, R.
Yang, M.
Viglietta, V.
Sheikh, S. I.
Fox, R. J.
EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 : 344 - 344
[42] 4-year follow-up of delayed-release dimethyl fumarate treatment in relapsing-remitting multiple sclerosis (RRMS): integrated clinical efficacy data from DEFINE, CONFIRM, and the ENDORSE extension study
Gold, R.
Phillips, J. T.
Bar-Or, A.
Kappos, L.
Zhang, R.
Yang, M.
Viglietta, V.
Sheikh, S. I.
Fox, R. J.
JOURNAL OF NEUROLOGY, 2014, 261 : S233 - S233
[43] Delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis - findings from a real-world setting in Russian Federation
Davydovskaya, M.
Pozhidaeva, N.
Dubchenko, E.
MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 934 - 935
[44] Longer-Term Follow-Up of the Efficacy of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: Integrated Analysis of DEFINE, CONFIRM and ENDORSE
Gold, Ralf
Giovannoni, Gavin
Phillips, J. Theodore
Fox, Robert
Zhang, Annie
Taylor, Catherine
Marantz, Jing
NEUROLOGY, 2016, 86
[45] Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing–Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies
Gold R.
Giovannoni G.
Phillips J.T.
Fox R.J.
Zhang A.
Marantz J.L.
Neurology and Therapy, 2016, 5 (1) : 45 - 57
[46] Clinical efficacy of delayed-release dimethyl fumarate in Asian patients with relapsing-remitting multiple sclerosis: integrated analysis of define and confirm
Hochman, S.
Fox, R. J.
Gold, R.
Phillips, J. T.
Okwuokeny, M.
Zhang, A.
Rana, J.
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2015, 357 : E306 - E307
[47] Absolute Lymphocyte Count in Patients with Relapsing-Remitting Multiple Sclerosis Treated with Delayed-release Dimethyl Fumarate: Considerations for Patient Management
Fox, Robert
Chan, Andrew
Gold, Ralf
Phillips, J. Theodore
Yang, Lili
Liu, Shifang
Prada, Claudia
Ray, Soma
Mehta, Devangi
Taylor, Catherine
Fay, Monica
NEUROLOGY, 2017, 88
[48] Clinical efficacy of delayed-release dimethyl fumarate in Hispanic patients with relapsing-remitting multiple sclerosis: integrated analysis of define and confirm
Hernandez, L.
Fox, R. J.
Gold, R.
Phillips, J. T.
Okwuokeny, M.
Zhang, A.
Rana, J.
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2015, 357 : E306 - E306
[49] A Retrospective Analysis of Real-World Discontinuation Rates with Delayed-Release Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis
Allan, Michelle
Grant, Lindsay
NEUROLOGY AND THERAPY, 2020, 9 (01) : 85 - 92
[50] Safety and Efficacy of Delayed-Release Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: 9 Years' Follow-up of DEFINE, CONFIRM, and ENDORSE (vol 13, pg 1, 2020)
Gold, R.
Arnold, D. L.
Bar-Or, A.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2020, 13

← 1 2 3 4 5 →